• Fri news: Pfizer’s $1B Chinese commitment. RFK Jr. and pharma. Eisai dials back Leqembi forecast. US diabetes burden increase. JNJ gets Varipulse approval. See more on our front page

BMS Gets Q2 Beat, Raises Full-Year Guidance as Cost-Cutting Initiative Continues

cafead

Administrator
Staff member
  • cafead   Jul 26, 2024 at 11:32: AM
via Bristol Myers Squibb on Friday reported strong second-quarter results, led by the blood thinner Eliquis and cancer therapy Opdivo, as it looks to cut $1.5 billion in costs by 2025.

article source